TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT02082639

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) in Healthy Female Adolescents Aged 9-14 Years

Cause of deathOther Automatic label, confidence 0.5, unverified. How labels are made.
“Because the Russian Authorities already approved the 2-dose Cervarix™ schedule, the study was no longer needed for registration and hence it was cancelled.”

The sponsor’s own words in the registry.

Life of this trial

201420152016Registered2014-03-06Planned start2015-02 (planned)Withdrawn (as of)2015-07-20

Vital statistics

Status
Withdrawn
Phase
Phase 3
Sponsor
GlaxoSmithKline
Sponsor type
Industry
Conditions
Infections, Papillomavirus
Interventions
Cervarix™; Havrix
Participants
0

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.